Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2019) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology, 185 (3). pp. 573-578. ISSN 0007-1048
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2018 British Society for Haematology and John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2018) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology. ISSN 0007-1048, which has been published in final form at https://doi.org/10.1111/bjh.15551. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | myeloma; clinical trials; myeloma therapy |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Oncology and Clinical Research (Leeds) The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 22 Aug 2018 10:18 |
Last Modified: | 29 Jun 2020 13:36 |
Status: | Published |
Publisher: | Wiley |
Identification Number: | 10.1111/bjh.15551 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:134841 |